U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274761) titled 'Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.' on Nov. 28.
Brief Summary: To assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).
Study Start Date: Oct. 17, 2024
Study Type: INTERVENTIONAL
Condition:
Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Intervention:
DRUG: Sunvozertinib
Participants will receive oral administration of sunvozer...